Tavneos is a medicine used to treat adults with severe, active granulomatosis with polyangiitis (GPA or Wegener’s granulomatosis) or microscopic polyangiitis (MPA), which are inflammatory conditions of the blood vessels. Tavneos is used as part of a combined treatment also including the medicines rituximab or cyclophosphamide. Tavneos contains the active substance avacopan. GPA and MPA are rare, and Tavneos was designated an ‘orphan medicine’ (a medicine used in rare diseases). Further information on the orphan designations can be found on the European Medicines Agency’s website ( [GPA](/en/medicines/human/orphan-designations/eu-3-14-1373): 19 November 2014; [MPA](/en/medicines/human/orphan-designations/eu-3-14-1372): 19 November 2014).
Therapeutic Indication
### Therapeutic indication Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
Therapeutic Area (MeSH)
N/AATC Code
L04
ATC Item
免疫抑制剂
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Avacopan | N/A | 阿伐可泮 |
EMA Name
Tavneos
Medicine Name
Tavneos
Aliases
N/ANo risk management plan link.
